Text Size

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components

Pfeiffer N., Traverso C.E., Lorenz K., Saarela V., Liinamaa J., Uusitalo H., Astakhov Y., Boiko E., Ropo A.


  • 2014
  • Advances in Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Mainz University Medical Center, Langenbeckstr. 1, Mainz, 55101, Germany; Clinica Oculistica, Di.N.O.G.M.I., University of Genoa, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy; Department of Ophthalmology, Medical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland; Department of Ophthalmology, University of Tampere and TAUH Eye Center, Tampere, Finland; First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Santen Oy, Clinical Research and Medical Affairs, Helsinki, Finland

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022